• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

突变型非小细胞肺癌中同时发生的突变：病例报告

Simultaneous Occurrence of Mutations in Mutant NSCLC: Case Reports.

作者信息

Resuli Blerina, Kauffmann-Guerrero Diego, Behr Jürgen, Tufman Amanda

机构信息

Department of Medicine V, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.

Comprehensive Pneumology Center Munich, German Center for Lung Research, Munich, Germany.

出版信息

JTO Clin Res Rep. 2024 Sep 7;5(12):100719. doi: 10.1016/j.jtocrr.2024.100719. eCollection 2024 Dec.

DOI:10.1016/j.jtocrr.2024.100719
PMID:39534574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11554893/
Abstract

mutation and amplification have been identified as distinct molecular targets in lung cancer with different therapeutic and prognostic values. The coexistence of and mutations is extremely rare, and therefore, no data exist on the best treatment in these cases.

摘要

突变和扩增已被确定为肺癌中具有不同治疗和预后价值的独特分子靶点。两种突变同时存在极为罕见，因此，尚无关于这些病例最佳治疗方法的数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d68/11554893/872a702e0bc5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d68/11554893/1ac3733ec0d5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d68/11554893/872a702e0bc5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d68/11554893/1ac3733ec0d5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d68/11554893/872a702e0bc5/gr2.jpg

相似文献

1
Simultaneous Occurrence of Mutations in Mutant NSCLC: Case Reports.突变型非小细胞肺癌中同时发生的突变：病例报告
JTO Clin Res Rep. 2024 Sep 7;5(12):100719. doi: 10.1016/j.jtocrr.2024.100719. eCollection 2024 Dec.
2
Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.阿法替尼克服携带获得性表皮生长因子受体（EGFR）L858R/T790M或L858R/S768I突变的非小细胞肺癌（NSCLC）伴软脑膜转移患者对埃克替尼和奥希替尼的耐药性：两例病例报告
Heliyon. 2023 Oct 8;9(10):e20690. doi: 10.1016/j.heliyon.2023.e20690. eCollection 2023 Oct.
3
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.在一家三级中心对已知表皮生长因子受体突变型非小细胞肺癌患者中各种代次的酪氨酸激酶抑制剂的原发性和获得性耐药的分子机制进行审计。
Clin Oncol (R Coll Radiol). 2022 Nov;34(11):e451-e462. doi: 10.1016/j.clon.2022.06.003. Epub 2022 Jul 7.
4
Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring Mutations.真实世界中阿法替尼治疗携带突变的晚期非小细胞肺癌的疗效。
Anticancer Res. 2022 Apr;42(4):2145-2157. doi: 10.21873/anticanres.15697.
5
Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report.表皮生长因子受体L861Q-L833F复合突变的非小细胞肺癌对阿法替尼和奥希替尼均有反应：一例报告
World J Clin Cases. 2021 Sep 26;9(27):8220-8225. doi: 10.12998/wjcc.v9.i27.8220.
6
Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.阿法替尼治疗奥希替尼获得性 EGFR L718V 突变介导耐药的肺腺癌患者的持久临床获益：病例报告及文献复习。
Ann Palliat Med. 2022 Mar;11(3):1126-1134. doi: 10.21037/apm-21-3731.
7
HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy.EGFR-TKI治疗进展后晚期NSCLC患者的HER2扩增及对EGFR-TKI联合吡咯替尼治疗的临床反应
Onco Targets Ther. 2021 Nov 18;14:5297-5307. doi: 10.2147/OTT.S335217. eCollection 2021.
8
Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.阿法替尼对比奥希替尼治疗非小细胞肺癌罕见 EGFR 突变患者的临床结局：一项汇总分析。
Oncologist. 2023 Jun 2;28(6):e397-e405. doi: 10.1093/oncolo/oyad111.
9
Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summary.阿法替尼治疗非小细胞肺癌罕见 EGFR 突变：通俗易懂的总结。
Future Oncol. 2023 Feb;19(4):291-297. doi: 10.2217/fon-2022-0842. Epub 2023 Feb 16.
10
First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.携带Leu858Arg表皮生长因子受体突变的晚期非小细胞肺癌患者的一线治疗策略：一项贝叶斯网络荟萃分析
Ther Adv Chronic Dis. 2022 Oct 17;13:20406223221125706. doi: 10.1177/20406223221125706. eCollection 2022.

本文引用的文献

1
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.HER2 改变对 EGFR 突变型非小细胞肺癌的影响。
Clin Lung Cancer. 2022 Jan;23(1):52-59. doi: 10.1016/j.cllc.2021.08.012. Epub 2021 Oct 18.
2
Targeting Aberrations in Non-Small Cell Lung Cancer with Osimertinib.奥希替尼靶向治疗非小细胞肺癌的研究进展
Clin Cancer Res. 2018 Jun 1;24(11):2594-2604. doi: 10.1158/1078-0432.CCR-17-1875. Epub 2018 Jan 3.
3
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.肺腺癌中的HER2突变：来自肺癌突变联盟的报告。
Cancer. 2017 Nov 1;123(21):4099-4105. doi: 10.1002/cncr.30869. Epub 2017 Jul 25.
4
Management of non-small cell lung cancer in the era of personalized medicine.个性化医疗时代的非小细胞肺癌管理
Int J Biochem Cell Biol. 2016 Sep;78:173-179. doi: 10.1016/j.biocel.2016.07.011. Epub 2016 Jul 15.
5
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice.晚期非小细胞肺癌在常规临床实践中的个性化治疗
Cancer Metastasis Rev. 2016 Mar;35(1):141-50. doi: 10.1007/s10555-016-9612-6.